{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:43:42Z","timestamp":1791639822239,"version":"4.3.4"},"reference-count":130,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.drudis.2024.104089","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T16:31:31Z","timestamp":1720283491000},"page":"104089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current understanding of the link between angiotensin-converting enzyme and pain perception"],"prefix":"10.1016","volume":"29","author":[{"given":"Kiran D.","family":"Bhilare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakashkumar","family":"Dobariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Hanak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick E.","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati S.","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104089_b0005","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/biology12050755","article-title":"Angiotensin-related peptides and their role in pain regulation","volume":"12","author":"Nemoto","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.drudis.2024.104089_b0010","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.joca.2013.08.014","article-title":"Synovial fluid levels of bradykinin correlate with biochemical markers for cartilage degradation and inflammation in knee osteoarthritis","volume":"21","author":"Bellucci","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.drudis.2024.104089_b0015","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1055\/s-0042-113183","article-title":"Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: cross-sectional cohort study","volume":"66","author":"Ueno","year":"2016","journal-title":"Drug Res"},{"key":"10.1016\/j.drudis.2024.104089_b0020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/jnc.15806","article-title":"Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders","volume":"166","author":"Santiago","year":"2023","journal-title":"J Neurochem"},{"key":"10.1016\/j.drudis.2024.104089_b0025","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1021\/cn500363g","article-title":"The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives","volume":"6","author":"Kaur","year":"2015","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2024.104089_b0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41577-021-00634-8","article-title":"Crosstalk between the renin\u2013angiotensin, complement and kallikrein\u2013kinin systems in inflammation","volume":"22","author":"Bekassy","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2024.104089_b0035","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.exphem.2003.08.018","article-title":"Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells","volume":"31","author":"Danilov","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.drudis.2024.104089_b0040","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.drudis.2014.06.026","article-title":"How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor","volume":"19","author":"Regulska","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.104089_b0045","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/ddc2030028","article-title":"Drugs of the kallikrein\u2013kinin system: an overview","volume":"2","author":"Marceau","year":"2023","journal-title":"Drugs Drug Candidates"},{"key":"10.1016\/j.drudis.2024.104089_b0050","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0014-2999(81)90158-8","article-title":"Potentiation of the morphine-induced respiratory rate depression by captopril","volume":"70","author":"Oktay","year":"1981","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0055","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pharep.2018.12.002","article-title":"Angiotensin converting enzyme and neprilysin inhibition alter pain response in dexhamethasone-induced hypertensive rats","volume":"71","author":"Aykan","year":"2019","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.drudis.2024.104089_b0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1440-1681.1983.tb00192.x","article-title":"Attenuation of the antihypertensive effect of captopril by the opioid receptor antagonist naloxone","volume":"10","author":"Millar","year":"1983","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.drudis.2024.104089_b0065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1470320313503694","article-title":"Renin\u2013angiotensin system in pain: existing in a double life?","volume":"15","author":"Bali","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.drudis.2024.104089_b0070","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3892\/etm.2015.2801","article-title":"Chronic nerve injury-induced Mas receptor expression in dorsal root ganglion neurons alleviates neuropathic pain","volume":"10","author":"Zhao","year":"2015","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.drudis.2024.104089_b0075","doi-asserted-by":"crossref","first-page":"e869","DOI":"10.1097\/PR9.0000000000000869","article-title":"Angiotensin receptors and neuropathic pain","volume":"6","author":"Balogh","year":"2021","journal-title":"Pain Rep"},{"key":"10.1016\/j.drudis.2024.104089_b0080","doi-asserted-by":"crossref","first-page":"E8057","DOI":"10.1073\/pnas.1721815115","article-title":"Macrophage angiotensin II type 2 receptor triggers neuropathic pain","volume":"115","author":"Shepherd","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2024.104089_b0085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bcpt.13453","article-title":"Renin-angiotensin system blockade modulates both the peripheral and central components of neuropathic pain in rats: role of calcitonin gene\u2013related peptide, substance P and nitric oxide","volume":"127","author":"Hegazy","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.drudis.2024.104089_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113825","article-title":"Downregulation of spinal angiotensin converting enzyme 2 is involved in neuropathic pain associated with type 2 diabetes mellitus in mice","volume":"174","author":"Yamagata","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2011.06.017","article-title":"Exploring the potential of telmisartan in chronic constriction injury-induced neuropathic pain in rats","volume":"667","author":"Jaggi","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1470320314556171","article-title":"Ameliorative potential of angiotensin-converting enzyme inhibitor (ramipril) on chronic constriction injury of sciatic nerve induced neuropathic pain in mice","volume":"16","author":"Kaur","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.drudis.2024.104089_b0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.diabet.2011.06.003","article-title":"Painful diabetic neuropathy: diagnosis and management","volume":"37","author":"Hartemann","year":"2011","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.drudis.2024.104089_b0110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ddr.21280","article-title":"Fosinopril prevents the development of tactile allodynia in a streptozotocin-induced diabetic rat model","volume":"76","author":"Araiza-Salda\u00f1a","year":"2015","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.drudis.2024.104089_b0115","doi-asserted-by":"crossref","first-page":"6719239","DOI":"10.1155\/2017\/6719239","article-title":"Efficacy of administration of ACE-inhibition for two years on diabetic autonomic and peripheral neuropathy in patients with diabetes mellitus","volume":"2017","author":"Didangelos","year":"2017","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.drudis.2024.104089_b0120","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/dc10-1303","article-title":"Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments","volume":"33","author":"Tesfaye","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.drudis.2024.104089_b0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/pgmj.2005.036137","article-title":"Diabetic neuropathy","volume":"82","author":"Bansal","year":"2006","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.drudis.2024.104089_b0130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11916-011-0181-7","article-title":"Diagnosis and treatment of pain in small-fiber neuropathy","volume":"15","author":"Hovaguimian","year":"2011","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.drudis.2024.104089_b0135","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1139\/apnm-2015-0145","article-title":"Effects of curcumin and captopril on the functions of kidney and nerve in streptozotocin-induced diabetic rats: role of angiotensin converting enzyme 1","volume":"40","author":"Abd Allah","year":"2015","journal-title":"Appl Physiol Nutr Metab"},{"key":"10.1016\/j.drudis.2024.104089_b0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2337\/diabetes.55.02.06.db05-0885","article-title":"ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats","volume":"55","author":"Coppey","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2024.104089_b0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF00572874","article-title":"Rapid reversal of a motor nerve conduction deficit in streptozotocin-diabetic rats by the angiotensin converting enzyme inhibitor lisinopril","volume":"30","author":"Cameron","year":"1993","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.drudis.2024.104089_b0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1529-8027.2002.2008_11.x","article-title":"Effects of lisinopril on streptozotocin-induced diabetic neuropathy in rats","volume":"7","author":"Aggarwal","year":"2002","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.drudis.2024.104089_b0155","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/(SICI)1097-4598(199907)22:7<920::AID-MUS16>3.0.CO;2-P","article-title":"Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide","volume":"22","author":"Kihara","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.drudis.2024.104089_b0160","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1440-1681.2004.04054.x","article-title":"Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin\u2013angiotensin system inhibitors","volume":"31","author":"Goto","year":"2004","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.drudis.2024.104089_b0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00592-011-0348-z","article-title":"Angiotensin-(1\u20137) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes","volume":"49","author":"Liu","year":"2012","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.drudis.2024.104089_b0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.niox.2013.12.007","article-title":"Ang-(1\u20137) activates the NO\/cGMP and ATP-sensitive K+ channels pathway to induce peripheral antinociception in rats","volume":"37","author":"Costa","year":"2014","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.drudis.2024.104089_b0175","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s41598-024-51572-z","article-title":"Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy","volume":"14","author":"Iwane","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.104089_b0180","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/BF00401368","article-title":"Correlations between nerve function and tissue oxygenation in diabetic patients: further clues to the aetiology of diabetic neuropathy?","volume":"35","author":"Young","year":"1992","journal-title":"Diabetologia"},{"key":"10.1016\/j.drudis.2024.104089_b0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1464-5491.1995.tb00482.x","article-title":"Is ACE inhibition with lisinopril helpful in diabetic neuropathy?","volume":"12","author":"Reja","year":"1995","journal-title":"Diabetic Med"},{"key":"10.1016\/j.drudis.2024.104089_b0190","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/S0140-6736(98)02478-7","article-title":"Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial","volume":"352","author":"Malik","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2024.104089_b0195","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/diacare.20.3.355","article-title":"Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy","volume":"20","author":"Kontopoulos","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.drudis.2024.104089_b0200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neures.2007.03.004","article-title":"Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat","volume":"58","author":"Lee","year":"2007","journal-title":"Neurosci Res"},{"key":"10.1016\/j.drudis.2024.104089_b0205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.npep.2016.06.001","article-title":"Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin","volume":"59","author":"Schlereth","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.drudis.2024.104089_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(03)00273-8","article-title":"Involvement of calcitonin gene-related peptide and its receptor in anti-nociception in the periaqueductal grey of rats","volume":"349","author":"Yu","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.drudis.2024.104089_b0215","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainres.2012.03.021","article-title":"Role of angiotensin II in the brain inflammatory events during experimental diabetes in rats","volume":"1453","author":"Vargas","year":"2012","journal-title":"Brain Res"},{"key":"10.1016\/j.drudis.2024.104089_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105020","article-title":"Inhibition of angiotensin converting enzyme induces mechanical allodynia through increasing substance P expression in mice","volume":"146","author":"Choi","year":"2021","journal-title":"Neurochem Int"},{"key":"10.1016\/j.drudis.2024.104089_b0225","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.neuint.2010.09.012","article-title":"Activation of the neurokinin-1 receptor in rat spinal astrocytes induces Ca2+ release from IP3-sensitive Ca2+ stores and extracellular Ca2+ influx through TRPC3","volume":"57","author":"Miyano","year":"2010","journal-title":"Neurochem Int"},{"key":"10.1016\/j.drudis.2024.104089_b0230","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pain.2005.03.045","article-title":"Enhancement of NMDA receptor phosphorylation of the spinal dorsal horn and nucleus gracilis neurons in neuropathic rats","volume":"116","author":"Gao","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.drudis.2024.104089_b0235","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjp.2008.159","article-title":"Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via PKC-and PKA-dependent phosphorylation of the NR1 subunit in mice","volume":"154","author":"Kim","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neulet.2010.06.044","article-title":"Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury","volume":"481","author":"Harford-Wright","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.drudis.2024.104089_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00304","article-title":"The role of substance P in secondary pathophysiology after traumatic brain injury","volume":"8","author":"Vink","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.drudis.2024.104089_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2022.102260","article-title":"Demystifying the dual role of the angiotensin system in neuropathic pain","volume":"94","author":"Kaur","year":"2022","journal-title":"Neuropeptides"},{"key":"10.1016\/j.drudis.2024.104089_b0255","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1305321110","article-title":"Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2","volume":"110","author":"Sprowl","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2024.104089_b0260","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1007\/s12035-021-02361-6","article-title":"Epigenetics involvement in oxaliplatin-induced potassium channel transcriptional downregulation and hypersensitivity","volume":"58","author":"Pereira","year":"2021","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.drudis.2024.104089_b0265","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jpain.2021.03.142","article-title":"Antioxidants improve oxaliplatin-induced peripheral neuropathy in tumor-bearing mice model: role of spinal cord oxidative stress and inflammation","volume":"22","author":"Agnes","year":"2021","journal-title":"J Pain"},{"key":"10.1016\/j.drudis.2024.104089_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.712442","article-title":"Ramipril alleviates oxaliplatin-induced acute pain syndrome in mice","volume":"12","author":"Bouchenaki","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0275","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1097\/j.pain.0000000000000690","article-title":"Angiotensin-(1\u20137)\/Mas receptor as an antinociceptive agent in cancer-induced bone pain","volume":"157","author":"Forte","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.drudis.2024.104089_b0280","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1007\/s12035-016-0275-7","article-title":"Potentiation of paclitaxel-induced pain syndrome in mice by angiotensin I converting enzyme inhibition and involvement of kinins","volume":"54","author":"Brusco","year":"2017","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.drudis.2024.104089_b0285","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ejp.1660","article-title":"Blockade of bradykinin receptors or angiotensin II type 2 receptor prevents paclitaxel-associated acute pain syndrome in mice","volume":"25","author":"Zanata","year":"2021","journal-title":"Eur J Pain"},{"key":"10.1016\/j.drudis.2024.104089_b0290","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.npep.2014.02.001","article-title":"Peptidergic intraepidermal nerve fibers in the skin contribute to the neuropathic pain in paclitaxel-induced peripheral neuropathy","volume":"48","author":"Ko","year":"2014","journal-title":"Neuropeptides"},{"key":"10.1016\/j.drudis.2024.104089_b0295","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.pain.2013.06.022","article-title":"Glia and pain: is chronic pain a gliopathy?","volume":"154","author":"Ji","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.drudis.2024.104089_b0300","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/HYPERTENSIONAHA.109.144600","article-title":"Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function","volume":"55","author":"Erd\u00f6s","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2024.104089_b0305","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/pharmaceutics14040848","article-title":"Neuroprotective effect of ramipril is mediated by AT2 in a mouse model of paclitaxel-induced peripheral neuropathy","volume":"14","author":"Bouchenaki","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2024.104089_b0310","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2016.06.050","article-title":"Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy","volume":"333","author":"Duggett","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.drudis.2024.104089_b0315","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.3390\/jcm11102939","article-title":"Renin-angiotensin-system inhibitors for the prevention of chemotherapy-induced peripheral neuropathy: OncoToxSRA, a preliminary cohort study","volume":"11","author":"Frachet","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2024.104089_b0320","doi-asserted-by":"crossref","first-page":"281","DOI":"10.36076\/ppj.2017.292","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers modulate the function of myelinated fibers after chemotherapy: a quantitative sensory testing study","volume":"20","author":"Roldan","year":"2017","journal-title":"Pain Physician"},{"key":"10.1016\/j.drudis.2024.104089_b0325","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3332\/ecancer.2020.1121","article-title":"Lack of association between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and pain improvement in patients with oral cancer","volume":"14","author":"Du","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.drudis.2024.104089_b0330","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2024.104089_b0335","first-page":"S1","article-title":"Canadian Headache Society guideline for migraine prophylaxis","volume":"39","author":"Pringsheim","year":"2012","journal-title":"Can J Neurol Sci"},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2024.104089_b0340","first-page":"15","article-title":"Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone","volume":"88","author":"L\u00fcscher","year":"1993","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.drudis.2024.104089_b0345","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pds.893","article-title":"Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy\u2014a pilot study","volume":"13","author":"Rahimtoola","year":"2004","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"10.1016\/j.drudis.2024.104089_b0350","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.hjh.0000220419.86149.11","article-title":"Involvement of the renin\u2013angiotensin system in migraine","volume":"24","author":"Tronvik","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.drudis.2024.104089_b0355","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1468-2982.1981.0104229.x","article-title":"Enkephalinase inhibition relieves pain syndromes of central dysnociception (migraine and related headache)","volume":"1","author":"Sicuteri","year":"1981","journal-title":"Cephalalgia"},{"key":"10.1016\/j.drudis.2024.104089_b0360","first-page":"475","article-title":"Captopril versus placebo in the prevention of hemicrania without aura. A randomized double-blind study","volume":"141","author":"Paterna","year":"1992","journal-title":"Clin Ter"},{"key":"10.1016\/j.drudis.2024.104089_b0365","first-page":"72","article-title":"Efficacy of enalapril in migraine prophylaxis: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Sonbolestan","year":"2013","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.drudis.2024.104089_b0370","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmj.322.7277.19","article-title":"Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study","volume":"322","author":"Schrader","year":"2001","journal-title":"Br Med J"},{"key":"10.1016\/j.drudis.2024.104089_b0375","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1526-4610.1995.hed3508470.x","article-title":"ACE inhibitors for prophylaxis of migraine headaches","volume":"35","author":"Bender","year":"1995","journal-title":"Headache"},{"key":"10.1016\/j.drudis.2024.104089_b0380","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1468-2982.2003.00627.x","article-title":"Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: results from the Italian group of pharmacoepidemiology in the elderly (GIFA)","volume":"23","author":"Onder","year":"2003","journal-title":"Cephalalgia"},{"key":"10.1016\/j.drudis.2024.104089_b0385","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1468-1331.2007.01764.x","article-title":"Efficacy of lisinopril in migraine prophylaxis\u2013an open label study","volume":"14","author":"Schuh-Hofer","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.drudis.2024.104089_b0390","first-page":"289","article-title":"Inhibitory control of angiotensin-converting enzyme by ramipril in migraine","volume":"18","author":"Park","year":"2013","journal-title":"Neurol Asia"},{"key":"10.1016\/j.drudis.2024.104089_b0395","first-page":"533","article-title":"Efficacy of enalapril in the treatment of migraine prophylaxis\u2013a clinical study","volume":"10","author":"Bindu","year":"2020","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0400","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1586\/14737175.2014.946408","article-title":"The renin\u2013angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis","volume":"14","author":"Ripa","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.drudis.2024.104089_b0405","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11940-016-0397-2","article-title":"ACE and ARB agents in the prophylactic therapy of migraine\u2014how effective are they?","volume":"18","author":"Halker","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.drudis.2024.104089_b0410","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/0253-7613.93840","article-title":"Renin angiotensin system: a novel target for migraine prophylaxis","volume":"44","author":"Nandha","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0415","first-page":"197","article-title":"Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels","volume":"51","author":"Tiret","year":"1992","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.drudis.2024.104089_b0420","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1172\/JCI117464","article-title":"Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme","volume":"94","author":"Morishita","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.104089_b0425","doi-asserted-by":"crossref","first-page":"19070","DOI":"10.1038\/s41598-023-45531-3","article-title":"Comprehensive analysis of genes associated with migraine in the Indian population: a meta-analysis of genetic association studies with trial sequential analysis","volume":"13","author":"Sudershan","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.104089_b0430","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neulet.2004.10.041","article-title":"Association of the insertion\/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura","volume":"374","author":"Kowa","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.drudis.2024.104089_b0435","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/cns.12712","article-title":"Angiotensin-converting enzyme gene rs4343 polymorphism increases susceptibility to migraine","volume":"23","author":"Abedin-Do","year":"2017","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.drudis.2024.104089_b0440","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/0024-3205(95)00043-6","article-title":"The renin angiotensin system and nociception in spontaneously hypertensive rats","volume":"56","author":"Irvine","year":"1995","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2024.104089_b0445","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0024-3205(01)01033-5","article-title":"Different potentiating effects of imidapril and enalapril on kaolin-induced writhing reaction in mice","volume":"68","author":"Sakamoto","year":"2001","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2024.104089_b0450","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5958\/0976-5506.2014.00270.8","article-title":"A study of effect of perindopril and candesartan on pain perception in albino rats","volume":"5","author":"Naidu","year":"2014","journal-title":"Indian J Public Health Res Dev"},{"key":"10.1016\/j.drudis.2024.104089_b0455","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1161\/01.HYP.31.5.1146","article-title":"Treatment with enalapril modifies the pain perception pattern in hypertensive patients","volume":"31","author":"Guasti","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2024.104089_b0460","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00004872-200203000-00024","article-title":"Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade","volume":"20","author":"Guasti","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.drudis.2024.104089_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173870","article-title":"Inhibitors of angiotensin I converting enzyme potentiate fibromyalgia-like pain symptoms via kinin receptors in mice","volume":"895","author":"Brusco","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0470","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcp.2019.06.023","article-title":"Kinins and their B1 and B2 receptors are involved in fibromyalgia-like pain symptoms in mice","volume":"168","author":"Brusco","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0475","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1152\/japplphysiol.01340.2003","article-title":"Kinin peptides in human trapezius muscle during sustained isometric contraction and their relation to pain","volume":"98","author":"Boix","year":"2005","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.drudis.2024.104089_b0480","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pain.2008.12.032","article-title":"The association between ACE inhibitors and the complex regional pain syndrome: suggestions for a neuro-inflammatory pathogenesis of CRPS","volume":"142","author":"de Mos","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.drudis.2024.104089_b0485","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.gene.2015.03.051","article-title":"Angiotensin converting enzyme and methylenetetrahydrofolate reductase gene variations in fibromyalgia syndrome","volume":"564","author":"Inanir","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.drudis.2024.104089_b0490","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/8755122515589976","article-title":"An observation of the correlation between ACEI and ARB medications and chronic pain medication utilization in a community pharmacy","volume":"31","author":"Babcock","year":"2015","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.drudis.2024.104089_b0495","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/AJP.0b013e318287a258","article-title":"Preoperative angiotensin-converting enzyme inhibitor use is not associated with increased postoperative pain and opioid use","volume":"29","author":"Turan","year":"2013","journal-title":"Clin J Pain"},{"key":"10.1016\/j.drudis.2024.104089_b0500","doi-asserted-by":"crossref","first-page":"E129","DOI":"10.1097\/BRS.0b013e31827b8c89","article-title":"Tissue renin-angiotensin system in the intervertebral disc","volume":"38","author":"Morimoto","year":"2013","journal-title":"Spine"},{"key":"10.1016\/j.drudis.2024.104089_b0505","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3225439","article-title":"Tissue renin-angiotensin system (tRAS) induce intervertebral disc degeneration by activating oxidative stress and inflammatory reaction","volume":"2021","author":"Sun","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.drudis.2024.104089_b0510","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/ard.59.2.125","article-title":"Angiotensin converting enzyme in human synovium: increased stromal [125I] 351A binding in rheumatoid arthritis","volume":"59","author":"Walsh","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2024.104089_b0515","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amjms.2019.10.014","article-title":"Differential expression of renin-angiotensin system-related components in patients with rheumatoid arthritis and osteoarthritis","volume":"359","author":"Wu","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.drudis.2024.104089_b0520","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.4081\/ejh.2014.2387","article-title":"Expressions of local renin-angiotensin system components in chondrocytes","volume":"58","author":"Tsukamoto","year":"2014","journal-title":"Eur J Histochem"},{"key":"10.1016\/j.drudis.2024.104089_b0525","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/taap.2000.8985","article-title":"Effects of captopril on interleukin-6, leukotriene B4, and oxidative stress markers in serum and inflammatory exudate of arthritic rats: evidence of antiinflammatory activity","volume":"168","author":"Agha","year":"2000","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0530","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/rheumatology\/keh398","article-title":"The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis","volume":"44","author":"Dalbeth","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.drudis.2024.104089_b0535","first-page":"603","article-title":"A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritis","volume":"17","author":"Bird","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.drudis.2024.104089_b0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2018.11.003","article-title":"Activation of local bone RAS by maternal excessive glucocorticoid participated in the fetal programing of adult osteopenia induced by prenatal caffeine exposure","volume":"363","author":"Wen","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0545","first-page":"24","article-title":"Reduced frequency of bone pain crises in patients with sickle cell disease given an angiotensin-converting enzyme inhibitor","volume":"68","author":"Egesie","year":"2019","journal-title":"West Indian Med J"},{"key":"10.1016\/j.drudis.2024.104089_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114121","article-title":"Effectiveness of losartan on infrapatellar fat pad\/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain","volume":"158","author":"Sriwatananukulkit","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2024.104089_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115842","article-title":"Angiotensin II triggers knee joint lesions in experimental osteoarthritis","volume":"145","author":"de S\u00e1","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.drudis.2024.104089_b0560","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0091-3057(98)00116-6","article-title":"The role of angiotensin II and of its receptor subtypes in the acetic acid-induced abdominal constriction test","volume":"62","author":"Georgieva","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.drudis.2024.104089_b0565","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0304-3959(99)00294-8","article-title":"Synergistic effect of cholecystokinin octapeptide and angiotensin II in reversal of morphine induced analgesia in rats","volume":"85","author":"Han","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.drudis.2024.104089_b0570","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-2999(79)90350-9","article-title":"Potentiation by angiotensin converting enzyme inhibitor, SQ, 14225, of the analgesic effect of morphine in mice","volume":"58","author":"T\u00fcrker","year":"1979","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0575","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-2999(80)90440-9","article-title":"Alterations by captopril of pain reactions due to thermal stimulation of the mouse foot: interactions with morphine, naloxone and aprotinin","volume":"63","author":"Ercan","year":"1980","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0580","first-page":"521","article-title":"Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its degradation in mouse brain","volume":"28","author":"Norman","year":"1985","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0585","first-page":"349","article-title":"Action of peptidase inhibitors on methionine5-enkephalin-arginine6-phenylalanine7 (YGGFMRF) and methionine5-enkephalin (YGGFM) metabolism and on electroacupuncture antinociception","volume":"230","author":"Chou","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2024.104089_b0590","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1254\/jjp.66.337","article-title":"Effects of a mixture of peptidase inhibitors (amastatin, captopril and phosphoramidon) on Met-enkephalin-, \u03b2-endorphin-, dynorphin-(1\u201313) and electroacupuncture-induced antinociception in rats","volume":"66","author":"Kishioka","year":"1994","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0595","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1126\/science.abl5130","article-title":"Angiotensin-converting enzyme gates brain circuit\u2013specific plasticity via an endogenous opioid","volume":"375","author":"Trieu","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.drudis.2024.104089_b0600","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-2999(82)90469-1","article-title":"Adrenal involvement in captopril-induced potentiation of morphine analgesia","volume":"85","author":"Das","year":"1982","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0605","first-page":"97","article-title":"Effects of lisinopril, captopril and losartan alone or in combination with morphine in light tail flick analgesic test","volume":"2","author":"Hajhashemi","year":"2009","journal-title":"Res Pharm Sci"},{"key":"10.1016\/j.drudis.2024.104089_b0610","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0014-2999(84)90607-1","article-title":"Enalapril, a new nonsulfhydryl angiotensin converting enzyme inhibitor, does not potentiate morphine analgesia","volume":"98","author":"Mojaverian","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104089_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135504","article-title":"Effect of captopril, an angiotensin-converting enzyme inhibitor, on morphine analgesia and tolerance in rats, and elucidating the inflammation and endoplasmic reticulum stress pathway in this effect","volume":"741","author":"Taskiran","year":"2021","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.drudis.2024.104089_b0620","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10571-013-9934-7","article-title":"Effect of subpressor dose of angiotensin II on pain-related behavior in relation with neuronal injury and activation of satellite glial cells in the rat dorsal root ganglia","volume":"33","author":"Pavel","year":"2013","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.drudis.2024.104089_b0625","doi-asserted-by":"crossref","first-page":"8405","DOI":"10.1021\/bi9011226","article-title":"Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme","volume":"48","author":"Kr\u00f6ger","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2024.104089_b0630","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1470320313489206","article-title":"C domain-selective inhibition of angiotensin-converting enzyme","volume":"14","author":"Ehlers","year":"2013","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.drudis.2024.104089_b0635","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/biom10040649","article-title":"Evolution of angiotensin peptides and peptidomimetics as angiotensin II receptor type 2 (AT2) receptor agonists","volume":"10","author":"Vasile","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2024.104089_b0640","first-page":"827","article-title":"Future drug discovery in renin-angiotensin-aldosterone system intervention","volume":"12","author":"Tamargo","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2024.104089_b0645","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0028-3908(85)90204-7","article-title":"Intracerebroventricular administration of angiotensin II attenuates morphine-induced analgesia in mice","volume":"24","author":"Kaneko","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2024.104089_b0650","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0304-3959(86)90214-9","article-title":"Evidence for the involvement of cerebral renin-angiotensin system (RAS) in stress analgesia","volume":"27","author":"Haulic\u0103","year":"1986","journal-title":"Pain"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T21:29:22Z","timestamp":1725053362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624002149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":130,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1359644624002149"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104089","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current understanding of the link between angiotensin-converting enzyme and pain perception","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104089"}}